





A.



B.



C.






FIG. 1

A.



B.



C.




FIG. 2




FIG. 3

## Tail Vein Injections







FIG. 4




DTBP




diimide activated crosslinker




diimide activated crosslinker with additional positive charge




di-NHS ester activated crosslinker with additional positive charge




di-NHS ester activated crosslinker with no additional positive charge



dithiosalicylic acid



Dithionicotinic acid



Ellman's reagent

FIG. 5




FIG. 6

Intravascular Gene Delivery





FIG. 7

**Immunofluorescent staining (black) for endothelial cells (CD31)**



**FIG. 8**